probucol has been researched along with Cognition Disorders in 6 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This PICASSO-COG (PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage for reducing COGnitive decline) substudy aims to assess the effects of cilostazol and/or probucol on cognitive function." | 5.22 | Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage. ( Hong, KS; Kwon, SU; Lee, J; Lee, JS; Oh, MS; Yu, KH, 2016) |
| " Therefore, we have tested whether the previously proven blood-brain barrier protective agent, probucol, can prevent blood-brain barrier breakdown and cognitive decline in a dietary-induced murine model of diabetic insulin resistance." | 3.91 | Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. ( Al-Salami, H; Brook, E; Fimognari, N; Lam, V; Mamo, JC; Mooranian, A; Nesbit, M; Takechi, R, 2019) |
| "Probucol treatment significantly protected against the behavioral and hippocampal biochemical changes induced by STZ." | 1.42 | Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice. ( Colle, D; de Bem, AF; de Oliveira, J; Dos Santos, AA; Farina, M; Hort, MA; Moreira, ELG; Peres, KC; Ribeiro, RP; Santos, DB, 2015) |
| "Moreover, middle-aged familial hypercholesterolemia (FH) subjects show a particularly high incidence of mild cognitive impairments (MCI)." | 1.39 | Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia. ( Aguiar, AS; de Bem, AF; de Carvalho, CR; de Oliveira, J; Farina, M; Moreira, EL; Prediger, RD; Santos, DB; Walz, R; Xikota, JC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, JL | 1 |
| Yu, C | 1 |
| Su, M | 1 |
| Yang, SM | 1 |
| Zhang, F | 1 |
| Chen, YY | 1 |
| Liu, JY | 1 |
| Jiang, YF | 1 |
| Zhong, ZG | 1 |
| Wu, DP | 1 |
| Mamo, JC | 1 |
| Lam, V | 1 |
| Brook, E | 1 |
| Mooranian, A | 1 |
| Al-Salami, H | 1 |
| Fimognari, N | 1 |
| Nesbit, M | 1 |
| Takechi, R | 1 |
| Moreira, EL | 2 |
| Aguiar, AS | 1 |
| de Carvalho, CR | 1 |
| Santos, DB | 3 |
| de Oliveira, J | 2 |
| de Bem, AF | 2 |
| Xikota, JC | 1 |
| Walz, R | 1 |
| Farina, M | 3 |
| Prediger, RD | 1 |
| Colle, D | 2 |
| Moreira, ELG | 1 |
| Peres, KC | 2 |
| Ribeiro, RP | 2 |
| Dos Santos, AA | 2 |
| Hort, MA | 1 |
| Yu, KH | 1 |
| Hong, KS | 1 |
| Oh, MS | 1 |
| Lee, J | 1 |
| Lee, JS | 1 |
| Kwon, SU | 1 |
| Souza, DO | 1 |
| Figueiredo, CP | 1 |
1 trial available for probucol and Cognition Disorders
| Article | Year |
|---|---|
Design and Rationale for a Cognitive Outcome Substudy in Ischemic Stroke Patients with High Risk of Cerebral Hemorrhage.
Topics: Adult; Anticholesteremic Agents; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Cognition Disorder | 2016 |
5 other studies available for probucol and Cognition Disorders
| Article | Year |
|---|---|
Probucol, a "non-statin" cholesterol-lowering drug, ameliorates D-galactose induced cognitive deficits by alleviating oxidative stress via Keap1/Nrf2 signaling pathway in mice.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cognition Disorders; Disease Models, Animal; Kelch- | 2019 |
Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Blood-Brain Barrier; Cerebral Cortex; Cognition | 2019 |
Effects of lifestyle modifications on cognitive impairments in a mouse model of hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Cognition Disorders; Founder Effect; Hyperlipoproteinemia Type II | 2013 |
Probucol mitigates streptozotocin-induced cognitive and biochemical changes in mice.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Amyloid Precursor Protein Secretases; | 2015 |
Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid β peptide in mice.
Topics: Amyloid beta-Peptides; Animals; Anticholesteremic Agents; Cognition Disorders; Hippocampus; Humans; | 2012 |